Background. Higher vancomycin trough levels are associated with increased risk of nephrotoxicity. However clinical data on the correlation between vancomycin pharmacodynamics (PD) parameter AUC 0-24 /MIC and nephrotoxicity are limited. Our aim was to investigate this relationship further in patients with methicillin resistant Staphylococcus Aureusbacteraemia (MRSAB).
Methods. A single centre retrospective observational cohort study involving 127 consecutive MRSAB patients was conducted. Demographics, clinical data and use of concomitant nephrotoxin were retrieved from medical records. Minimum inhibitory concentration (MIC) was obtained using broth microdilution (BMD). Acute kidney injury (AKI) was defined as ≥0.5 mg/L or 50% increase in serum creatinine from baseline on 2 or more consecutive measurements. Classification and regression tree (CART) analysis was performed to identify a vancomycin AUC 0-24 /MIC threshold for AKI.
Results. AKI was observed in 15.7% of patients (20/127). Clinical characteristics were similar between patients with and without AKI (107/120). The mean vancomycin trough level was 13.8mg/L with higher levels associated with AKI compared to patients with no kidney injury (17.2 mg/L vs 13.1 mg/L; p = 0.007). Similar to previous studies the probability of AKI increased when vancomycin trough concentrations were above 15mg/L. A vancomycin AUC 0-24 /MIC target of > 591 (mg*h/L) was detected by CART analysis; with AKI occurring in 30.3% (10/33) compared to 10.6% (10/94) in patient achieving PD targets above and below 591 respectively ( p = 0.012). The only other risk factor for AKI on univariate analysis was concomitant use of nephrotoxins (18/20, 90% vs 53/107, 49.5%; p = 0.001). On multivariate logistic regression analysis vancomycin PD targets (OR 3.5, 95% CI 1.2-10.2; p = 0.022) and concomitant nephrotoxins use (OR 8.35, ; p = 0.007) were the only independent predictors of AKI despite age, severity of illness and ICU stay included in the model a priori.
Conclusion. AKI is associated with vancomycin PD targets. An increased incidence of AKI is noted with higher AUC 0-24 /MIC values beyond the currently recommended targets for treatment success.
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